# A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

> clinical trial · VERIFIED · 2026-08-06

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Locally Advanced Head and Neck Squamous Cell Carcinoma

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06129864

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.